China Market: Hainan Boao Lecheng Establishes World’s First "Longevity Medicine Pilot Framework"

Longevitymedical tourism
Written By camellia chen

  • 【Abstract】: (Policy Update) The Hainan Boao Lecheng International Medical Tourism Pilot Zone has officially launched a regulatory framework specifically for "Longevity and Preventative Medicine." This allows the fast-track importation and clinical application of unapproved anti-aging therapies, including next-gen senolytics, NAD+ precursors, and advanced exosome infusions.

  • Business Insight: Hainan is aggressively positioning itself as the "Anti-Aging Capital of Asia," directly competing with Switzerland and Japan. For international longevity biotech firms, Boao is the ultimate sandbox to commercialize therapies for the wealthy Chinese demographic. CMTF exhibitors should leverage this zone to legally market cutting-edge cellular therapies to domestic patients without them leaving the country.

  • 【Keywords】: #LongevityMedicine #HainanBoao #AntiAgingPolicy

  • 【Source】: Hainan Daily / Boao Lecheng Administration (Feb 24, 2026)

camellia chen
Previous

Regenerative Breakthrough: Japan Fast-Tracks iPSC-Derived Cell Therapy for Premature Ovarian Failure
Next

Big Biotech: Longevity Giant Altos Labs Signs Exclusive Clinical Trial Pact with Peking Union Medical College Hospital